Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price & Analysis
Arcturus Therapeutics Holdings Inc. (ARCT) rose 0.56% to USD 7.16 as of June 10, 2026 at 02:36 UTC, according to Nexqual real-time market data.
ARCT last closed at USD 7.12; the session ranged USD 6.92–7.43 on volume of 242,010 shares. Market capitalization is $203.51M, with a 52-week range of USD 5.85–24.17 (NGM). Source: Nexqual, June 10, 2026 at 02:36 UTC.
Key Statistics (as of June 10, 2026 at 02:36 UTC)
| Price | USD 7.16 |
|---|---|
| Change | ▲ 0.56% (up) |
| Previous Close | USD 7.12 |
| Open | USD 7.28 |
| Day Range | USD 6.92 – 7.43 |
| 52-Week Range | USD 5.85 – 24.17 |
| Volume | 242,010 shares |
| Market Cap | $203.51M |
| Exchange | NGM |
Technical Analysis (ARCT)
Nexqual's technical model rates ARCT "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:36 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.33 (neutral) |
| vs SMA50 | Below (USD 8.09) |
| MACD | -0.19 (negative) |
Analyst Ratings (ARCT)
Wall Street analysts rate ARCT "None" based on 9 analysts, with a mean price target of USD 19.89 (range USD 8–40), per Nexqual as of June 10, 2026 at 02:36 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 19.89 |
| High Target | USD 40 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 9 / 3 / 0 |
Earnings (ARCT)
| Next Earnings Date | 2026-05-07 |
|---|---|
| EPS Estimate | USD -1.03 |
| Revenue Estimate | $3.20M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.95 vs est -1.01 ▲ beat |
| 2025-12-31 | USD -1.03 vs est -0.76 ▼ miss |
| 2025-09-30 | USD -0.49 vs est -0.8 ▲ beat |
| 2025-06-30 | USD -0.34 vs est -0.85 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financials & Fundamentals (ARCT)
| Total Revenue | $54.71M |
|---|---|
| Revenue Growth (YoY) | -93.00% |
| Gross Margin | -80.67% |
| Operating Margin | -1403.74% |
| Profit Margin | -143.80% |
| ROE | -37.01% |
| Debt / Equity | 12.54 |
| Current Ratio | 6.31 |
| Total Cash | $211.38M |
| Total Debt | $23.99M |
| Free Cash Flow | $11.29M |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financial Health Score (ARCT)
Nexqual rates Arcturus Therapeutics Holdings Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:36 UTC.
| Growth | Critical — Revenue -46% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $211M cash vs $24M debt, net cash position |
| Cash Flow | Solid — FCF $11M, 14% margin |
| Efficiency | Critical — ROE -37%, ROA -19.1% |
Ownership (ARCT)
| Insider Ownership | +7.99% |
|---|---|
| Institutional Ownership | +80.27% |
| Shares Outstanding | 28.42M |
| Float | 26.15M |
| Short % of Float | +29.45% |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Leadership (ARCT)
Arcturus Therapeutics Holdings Inc. is led by Joseph E. Payne M.Sc. (age 53), Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 02:36 UTC.
| Founder, President, CEO & Director | Joseph E. Payne M.Sc. (age 53) |
|---|---|
| Founder, Chief Scientific Officer, COO & Secretary | Padmanabh Chivukula (age 46) |
| Chief Financial Officer | Dennis M. Mulroy (age 70) |
| Vice President and Head of IR/PR & Marketing | Neda Safarzadeh |
Major Backers & Investors (ARCT)
Notable institutional backers of Arcturus Therapeutics Holdings Inc. include Federated Hermes, Inc., ARK Invest, Sumitomo Mitsui Trust Group, Inc., according to Nexqual as of June 10, 2026 at 02:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Federated Hermes, Inc. | 23.09% |
| ARK Invest | 18.75% |
| Sumitomo Mitsui Trust Group, Inc. | 8.05% |
| Amova Asset Management Americas Inc | 8.05% |
| Two Sigma Investments, LP | 3.81% |
| Fidelity | 0.87% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 13.04% |
| BlackRock | 12.11% |
| Geode Capital | 2.33% |
| State Street | 1.91% |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
From Arcturus Therapeutics Holdings Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- In December 2022, we entered into a Collaboration and License Agreement ("CSL Collaboration Agreement") with CSL Seqirus, a part of CSL Limited and one of the world's leading influenza vaccine providers, for the global exclusive rights to research, develop, manufacture and commercialize self-amplifying mRNA vaccines against COVID-19, influenza and up to three other infectious diseases and global non-exclusive rights to pandemic pathogens.
- KOSTAIVE BLA Submission On September 5, 2025, the week prior to the planned Biologics License Application ("BLA") submission related to KOSTAIVE, the FDA requested that the submission of the BLA filing be delayed due to the FDA's expectation of providing additional advice.
- Our proprietary self-amplifying mRNA technology platform, or STARR ® ("STARR"), has been demonstrated to induce a robust, longer-lasting and broader humoral immune response at lower dose levels than conventional mRNA-based vaccines.
- Our proprietary LNP delivery system, LUNAR ® ("LUNAR"), is intended to address the major hurdle in RNA drug development, namely the effective and safe delivery of RNA to disease-relevant target tissues.
Partnerships
- In our vaccine program, we have partnered with CSL Seqirus, one of the world's leading influenza vaccine providers, on the development and commercialization of mRNA vaccines for COVID-19, influenza and three other infectious diseases.
- In our influenza vaccine franchise, a Phase 1 clinical trial of our seasonal influenza candidate was conducted in 2024-2025 under our collaboration with CSL Seqirus, and a BARDA-funded Phase 1 clinical trial of our H5N1 pandemic flu candidate was initiated in December 2024 and is ongoing.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TWST | Twist Bioscience Corporation | USD 70.06 | ▲ 1.21% |
| CDNA | CareDx, Inc. | USD 22.75 | ▲ 2.25% |
| PSNL | Personalis, Inc. | USD 9.75 | ▼ 9.3% |
| PACB | Pacific Biosciences of Californ | USD 1.37 | ▼ 5.52% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 3.88 | ▼ 8.27% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:36 UTC. This page is informational and not investment advice.